An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) - 28/03/15
, Roxana Mehran, MD b, Christoph Bode, MD c, Johnathan Halperin, MD b, Freek Verheugt, MD d, Peter Wildgoose, PhD e, Martin van Eickels, MD f, Gregory Y.H. Lip, MD g, Marc Cohen, MD h, Steen Husted, MD i, Eric Peterson, MD j, Keith Fox, MD kRiassunto |
Background |
Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy), but neither the duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. Recent studies also suggest dual pathway therapy with clopidogrel plus oral anticoagulation therapy may be superior, and other studies suggest that novel oral anticoagulants such as rivaroxaban may further improve patient outcomes.
Design |
PIONEER AF-PCI (ClinicalTrials.gov NCT01830543) is an exploratory, open-label, randomized, multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and 1 vitamin K antagonist (VKA) treatment strategy in subjects who have paroxysmal, persistent, or permanent nonvalvular AF and have undergone PCI with stent placement. Approximately 2,100 subjects will be randomized in a 1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months (a WOEST trial–like strategy), or rivaroxaban 2.5 mg twice daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, an ATLAS trial–like strategy), or dose-adjusted VKA once daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, traditional triple therapy). All patients will be followed up for 12 months for the primary composite end point of Thrombolysis in Myocardial Infarction major bleeding, bleeding requiring medical attention, and minor bleeding (collectively, clinically significant bleeding).
Conclusion |
The PIONEER AF-PCI study is the first randomized comparison of VKA vs novel oral anticoagulant therapy in patients with NVAF receiving antiplatelet therapy after PCI to assess the relative risks of bleeding complications.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Stuart J. Connolly, MD, served as guest editor for this article. |
|
| RCT No. NCT01830543. |
Vol 169 - N° 4
P. 472 - aprile 2015 Ritorno al numero
Articolo precedente
- Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)
- Gregory Y.H. Lip, Christoph Hammerstingl, Francisco Marin, Riccardo Cappato, Isabelle Ling Meng, Bodo Kirsch, Eolo Morandi, Martin van Eickels, Ariel Cohen
- Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial
- Michael R. Jaff, Kenneth Rosenfield, Dierk Scheinert, Krishna Rocha-Singh, James Benenati, Mark Nehler, Christopher J. White
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?